Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

BACKGROUND: Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects of a randomised trial comparing conventional and hypofractionated radiotherapy after 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Dearnaley, David, Syndikus, Isabel, Mossop, Helen, Khoo, Vincent, Birtle, Alison, Bloomfield, David, Graham, John, Kirkbride, Peter, Logue, John, Malik, Zafar, Money-Kyrle, Julian, O'Sullivan, Joe M, Panades, Miguel, Parker, Chris, Patterson, Helen, Scrase, Christopher, Staffurth, John, Stockdale, Andrew, Tremlett, Jean, Bidmead, Margaret, Mayles, Helen, Naismith, Olivia, South, Chris, Gao, Annie, Cruickshank, Clare, Hassan, Shama, Pugh, Julia, Griffin, Clare, Hall, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961874/
https://www.ncbi.nlm.nih.gov/pubmed/27339115
http://dx.doi.org/10.1016/S1470-2045(16)30102-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961874/
https://www.ncbi.nlm.nih.gov/pubmed/27339115
http://dx.doi.org/10.1016/S1470-2045(16)30102-4

Ejemplares similares